This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Effects of HCBP6 protein on transact-ivating function of HCV core protein
Jun Cheng, Ke Li, Yan Liu, Lin Wang, Yin-Ying Lu, Yan-Wei Zhong
Jun Cheng, Ke Li, Yan Liu, Lin Wang, Yin-Ying Lu, Yan-Wei Zhong, Gene Therapy Research Center, Institute of Infectious Diseases, Chinese PLA 302 Hospital, Beijing 100039, China
Supported by: National Natural Science Foundation No. C03011402,No. C30070689,No. C39970674. and Returned Scholarship of General Logistics Department of Chinese PLA of China.
Correspondence to: Dr. Jun Cheng, Gene Therapy Research Center, Institute of Infectious Diseases, The 302 Hospital of PLA, 100 Xisihuanzhong Road, Beijing 100039, China. cj@genetherapy.com.cn
Received: November 13, 2003 Revised: December 1, 2003 Accepted: December 16, 2003 Published online: April 15, 2004
AIM: To study the inhibitory effects of HCBP6 on the transactivating effect of HCV core protein.
METHODS: The recombinant vectors expressive HCV core protein and HCBP6 protein were constructed, respectively, by routine molecular techniques. The hepatoblastoma cell line HepG2 were co-transfected. The chloramphenicol transferase (CAT) expressive levels under the SV40 early promoter were determined by an enzyme-linked immuno-sorbent assay (ELISA) kit.
RESULTS: The recombinant vectors of pcDNA3.1(-)-HCBP6 and pcDNA3.1(-)-core were constructed, and demonstrated correctly by restriction enzyme digestion and sequencing analysis. The hepatoblastoma cell line HepG2 was transfected with the vector alone or combined, respectively. The expression level of CAT indicated that the inhibitory rate was 40.4%-62.3%.
CONCLUSION: The expression of HCBP6 has inhibitory effects on the transacting activity of HCV core protein.
Key Words: N/A
Citation: Cheng J, Li K, Liu Y, Wang L, Lu YY, Zhong YW. Effects of HCBP6 protein on transact-ivating function of HCV core protein. Shijie Huaren Xiaohua Zazhi 2004; 12(4): 809-812
Li K, Wang L, Cheng J, Lu YY, Zhang LX, Mu JS, Hong Y, Liu Y, Duan HJ, Wang G. Interaction between hepatitis C virus core protein and translin protein-a possible molecular mechanism for hepatocellular carcinoma and lymphoma caused by hepatitis C virus.World J Gastroenterol. 2003;9:300-303.
[PubMed] [DOI]
Shirakata Y, Koike K. Hepatitis B virus x protein induces cell death by causing loss of mitochondrial membrane potential.J Biol Chem. 2003;278:22071-22078.
[PubMed] [DOI]
Goto T, Kato N, Yoshida H, Otsuka M, Moriyama M, Shiratori Y, Koike K, Matsumura M, Omata M. Synergistic activation of the serum response element-dependent pathway by hepatitis B virus x protein and large-isoform hepatitis delta antigen.J Infect Dis. 2003;187:820-828.
[PubMed] [DOI]
Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, Haussinger D. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3.FASEB J. 2003;17:488-490.
[PubMed] [DOI]
Ning Q, Berger L, Luo X, Yan W, Gong F, Dennis J, Levy G. STAT1 and STAT3 alpha/beta splice form activation predicts host responses in mouse hepatitis virus type 3 infection.J Med Virol. 2003;69:306-312.
[PubMed] [DOI]
Lin WJ, Li J, Lee YF, Yeh SD, Altuwaijri S, Ou JH, Chang C. Suppression of hepatitis B virus core promoter by the nuclear orphan receptor TR4.J Biol Chem. 2003;278:9353-9360.
[PubMed] [DOI]
Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, Mira E, Iniguez MA, Fresno M, Martinez-A C, Arroyo AG, Lopez-Cabrera M. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.J Clin Invest. 2002;110:1831-1838.
[PubMed] [DOI]
Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, Manns MP, Kubicka S. Involvement of TRAIL and its receptors in viral hepatitis.FASEB J. 2003;17:94-96.
[PubMed] [DOI]
Petrulis JR, Kusnadi A, Ramadoss P, Hollingshead B, Perdew GH. The hsp90 Co-chaperone XAP2 alters importin beta recognition of the bipartite nuclear localization signal of the Ah receptor and represses transcriptional activity.J Biol Chem. 2003;278:2677-2685.
[PubMed] [DOI]
